France · Delayed Price · Currency is EUR Virbac Earnings Call Transcripts
Fiscal Year 2025
-
Delivered 7.9% organic revenue growth and stable margins in 2025, with strong performance across all regions and segments. Record R&D and CapEx investments, a key acquisition, and a refreshed strategy position the company for continued outperformance, with 2026 guidance targeting higher margins and robust cash flow.
-
Solid H1 2025 results with 5.6% organic growth, strong performance across most regions, and robust new product launches. EBIT margin declined due to temporary effects, but full-year guidance and 2030 margin targets are reaffirmed. CapEx and M&A activity remain high priorities.
Fiscal Year 2024
-
Revenue grew 13.6% in 2024, driven by balanced organic and acquisition growth, with record EBIT margin and strong cash flow. Outlook for 2025 is 4%-6% revenue growth, stable profitability, and continued high CapEx for transformation.
-
Strong organic and acquisition-driven growth led to record profitability, with all major segments and regions contributing. Guidance for 2024 was raised, and major CapEx and R&D investments continue, while leadership transitions are underway.